These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 2313718

  • 1. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
    Gianni L, Viganò L, Surbone A, Ballinari D, Casali P, Tarella C, Collins JM, Bonadonna G.
    J Natl Cancer Inst; 1990 Mar 21; 82(6):469-77. PubMed ID: 2313718
    [Abstract] [Full Text] [Related]

  • 2. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
    Graham MA, Bissett D, Setanoians A, Hamilton T, Kerr DJ, Henrar R, Kaye SB.
    J Natl Cancer Inst; 1992 Apr 01; 84(7):494-500. PubMed ID: 1545439
    [Abstract] [Full Text] [Related]

  • 3. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
    Pippa LF, Oliveira ML, Rocha A, de Andrade JM, Lanchote VL.
    J Pharm Biomed Anal; 2020 Jun 05; 185():113231. PubMed ID: 32163849
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P.
    Cancer Chemother Pharmacol; 1997 Jun 05; 40(1):1-10. PubMed ID: 9137522
    [Abstract] [Full Text] [Related]

  • 5. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J, Geijssen GJ, Munniksma CN, Vermorken JB, van der Vijgh WJ.
    J Clin Oncol; 1992 Dec 05; 10(12):1897-906. PubMed ID: 1453205
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998 Dec 05; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats.
    Zeng X, Cai H, Yang J, Qiu H, Cheng Y, Liu M.
    Biomed Pharmacother; 2019 Aug 05; 116():108964. PubMed ID: 31102935
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
    Robert J, Armand JP, Huet S, Klink-Alakl M, Recondo G, Hurteloup P.
    J Clin Oncol; 1992 Jul 05; 10(7):1183-90. PubMed ID: 1607922
    [Abstract] [Full Text] [Related]

  • 10. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
    Graham MA, Newell DR, Foster BJ, Gumbrell LA, Jenns KE, Calvert AH.
    Cancer Res; 1992 Feb 01; 52(3):603-9. PubMed ID: 1732048
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.
    Yoshida H, Goto M, Honda A, Nabeshima T, Kumazawa T, Inagaki J, Yamanaka N, Ota K.
    Cancer Chemother Pharmacol; 1994 Feb 01; 33(6):450-4. PubMed ID: 8137454
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic and pharmacokinetic aspects of iodo-doxorubicin.
    Mross K, Mayer U, Zeller W, Becker K, Hossfeld DK.
    Oncol Res; 1992 Feb 01; 4(6):227-31. PubMed ID: 1421615
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.
    Graham MA, Newell DR, Foster BJ, Calvert AH.
    Cancer Chemother Pharmacol; 1989 Feb 01; 23(1):8-14. PubMed ID: 2909292
    [Abstract] [Full Text] [Related]

  • 15. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P.
    Cancer Res; 1993 Oct 15; 53(20):4837-42. PubMed ID: 8402670
    [Abstract] [Full Text] [Related]

  • 16. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A.
    Eur J Cancer; 2017 Nov 15; 86():240-247. PubMed ID: 29055839
    [Abstract] [Full Text] [Related]

  • 17. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.
    Fuse E, Kobayashi S, Inaba M, Suzuki H, Sugiyama Y.
    J Natl Cancer Inst; 1994 Jul 06; 86(13):989-96. PubMed ID: 8024657
    [Abstract] [Full Text] [Related]

  • 18. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
    Licata S, Saponiero A, Mordente A, Minotti G.
    Chem Res Toxicol; 2000 May 06; 13(5):414-20. PubMed ID: 10813659
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.
    Edwards DM, Marrari P, Efthymiopoulos C, Basileo G, Fraier D, Pianezzola E, Strolin-Benedetti M.
    Drug Metab Dispos; 1991 May 06; 19(5):938-45. PubMed ID: 1686240
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of weekly low dose doxorubicin.
    Frenay M, Milano G, Renee N, Pons D, Khater R, François E, Thyss A, Namer M.
    Eur J Cancer Clin Oncol; 1989 Feb 06; 25(2):191-5. PubMed ID: 2702975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.